Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 3/2024

10-02-2024 | Chronic Myeloid Leukemia | REVIEW

BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

Authors: Jenna M. Menger, Ryan S. Sathianathen, Kathleen M. Sakamoto, Nobuko Hijiya

Published in: Current Oncology Reports | Issue 3/2024

Login to get access

Abstract

Purpose of Review

The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.

Recent Findings

There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children.

Summary

Chronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses. Use of more specific TKIs may mitigate some of the side effects specific to the pediatric cohort. Children with advanced phase CML should achieve a complete hematologic remission with use of a second-generation TKI prior to transplant to achieve the best outcome.
Literature
1.
SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023. [updated: 2023 Nov 16; cited 2024 Feb 9]. Available from: https://​seer.​cancer.​gov/​statistics-network/​explorer/​. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries.
2.
Athale U, et al. Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66(9):e27827.PubMedPubMedCentralCrossRef
3.
4.
Haznedaroğlu İC, Kuzu I, İlhan O. WHO 2016 Definition of chronic myeloid leukemia and tyrosine kinase inhibitors. Turk J Haematol. 2020;37(1):42–7.PubMedPubMedCentral
5.
6.
Sembill S, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: international pediatric CML expert panel recommendations. Leukemia. 2023;37:505–17.PubMedPubMedCentralCrossRef
7.
Millot F, et al. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica. 2017;102(10):1704–8.PubMedPubMedCentralCrossRef
8.
Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374–84.PubMedCrossRef
9.
Cortes JE, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.PubMedPubMedCentralCrossRef
10.
Giles FJ, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–5.PubMedCrossRef
11.
Douxfils J, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625–32.PubMedCrossRef
12.
Larson RA, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up [published correction appears in Leukemia. 2012;26:2302]. Leukemia. 2012;26(10):2197–203.PubMedCrossRef
13.
Gore L, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36(13):1330–8.PubMedPubMedCentralCrossRef
14.
Hijiya N, et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019;134(23):2036–45.PubMedPubMedCentralCrossRef
15.
Hijiya N, et al. Pharmacokinetics of nilotinib in pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia. Clin Cancer Res. 2020;26(4):812–20.PubMedCrossRef
16.
•• Brivio E, et al. Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the Phase I Part of Study ITCC054/COG AAML1921. J ClinOncol. 2023;JCO2300897. The results from the phase 1 component of a trial of bosutinib in children with resistant or intolerant Ph+ CML demonstrated a tolerable toxicity profile in the three doses evaluated as well as efficacy comparable to other second generation TKIs in this population.
17.
Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231–7.PubMedCrossRef
18.
Tauer JT, et al. Impact of the tyrosine kinase inhibitors imatinib, dasatinib, and bosutinib in young rats on the vertebral body. Blood. 2013;122(21):1472.CrossRef
19.
Hochhaus A, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.PubMedPubMedCentralCrossRef
20.
Cortes JE, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in treatment-naïve chronic myeloid leukemia patients Trial. J Clin Oncol. 2016;34(20):2333–40.PubMedPubMedCentralCrossRef
21.
Deininger MW, et al. Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385–415.PubMedCrossRef
22.
23.
Millot F, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011;29(20):2827–32.PubMedCrossRef
24.
Inzoli E, et al. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. Am J Hematol. 2022;97(8):1075–85.PubMedPubMedCentralCrossRef
25.
Kurosawa H, et al. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer. 2018;65(12):e27368.PubMedCrossRef
26.
Soverini S, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–15.PubMedCrossRef
27.
•• Hughes TP, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–2326. A phase 1 study of asciminib in adults with refractory CML or intolerance to other TKI therapy demonstrated tolerability as well as durable and sustained responses in patients with both chronic and accelerated phase CML and those with T315I mutations.
28.
Réa D, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–41.PubMedPubMedCentralCrossRef
29.
Cortes JE, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404.PubMedPubMedCentralCrossRef
30.
Rossoff J, et al. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020;189(2):363–8.PubMedCrossRef
31.
Jiang Q, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):113.PubMedPubMedCentralCrossRef
32.
Li X, et al. Olverembatinib treatment in pediatric patients with relapsed philadelphia-chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2023;S2152–2650(23):00140–4.
33.
Jorge E, et al. Efficacy and safety of vodobatinib in patients (pts) with chronic phase philadelphia positive chronic myeloid leukemia (Ph+ CML): a sub group analysis by lines of tyrosine kinase inhibitor (TKI) Therapy. Blood. 2022;140(Supplement 1):205–7.CrossRef
34.
Turkina AG, et al. PF-114 in patients failing prior tyrosine kinase-inhibitor therapy including BCR::ABL1T315I. Blood. 2021;138(Supplement 1):1482.CrossRef
35.
36.
Cortes JE, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015;121(10):1637–44.ADSPubMedCrossRef
37.
Alvandi F, et al. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2014;19(1):94–9.PubMedCrossRef
38.
39.
Hehlmann R, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–406.PubMedPubMedCentralCrossRef
40.
Millot F, et al. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer. 2019;115:17–23.PubMedCrossRef
41.
Porkka K, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005–12.PubMedCrossRef
42.
Chiba A, et al. Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. Int J Hematol. 2018;108:640–6.PubMedCrossRef
43.
Sembill S, et al. Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics. Br J Haematol. 2021;193:613–8.PubMedCrossRef
44.
Radujkovic A, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transpl. 2019;25:2008–16.CrossRef
45.
46.
Krumbholz M, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosome Cancer. 2012;51(11):1045–53.CrossRef
47.
Branford S, et al. International CML Foundation Genomics Alliance. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835–50.PubMedPubMedCentralCrossRef
48.
Schönfeld L, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022;36(9):2242–9.PubMedPubMedCentralCrossRef
49.
Meyran D, et al. Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: a report from the I-CML-Ped Study. Eur J Cancer. 2020;137:224–34.PubMedCrossRef
50.
51.
Hoffmann VS, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 european countries. Leukemia. 2015;29(6):1336–43.PubMedCrossRef
52.
Samis J, et al. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332–8.PubMedCrossRef
53.
Narayanan KR, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013;60(7):1148–53.PubMedCrossRef
54.
• Walia R, et al. Acquired neuro-secretory defect in growth hormone secretion due to Imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia. Pediatr Hematol Oncol. 2020;37(2):99–108. Four children with CP-CML in remission on imatinib therapy, who had evidence of growth impairment and low levels of IGH-1, were treated with growth hormone and had an improvement in their growth velocity.
55.
Robertson HF, Buckton MJ, Apperley JF. Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations. Expert Rev Hematol. 2023;16(5):325–32.PubMedCrossRef
56.
Ali R, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280(2):169–75.PubMedCrossRef
57.
Chelysheva E, et al. S881 Pregnancy outcome in female patients with chronic myeloid leukemia worldwide: analysis of 305 cases of the European leukaemia net registry. Hemasphere. 2019;3(S1):395–6.CrossRef
58.
Yazdani Brojeni P, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265–8.PubMedCrossRef
Metadata
Title
BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach
Authors
Jenna M. Menger
Ryan S. Sathianathen
Kathleen M. Sakamoto
Nobuko Hijiya
Publication date
10-02-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 3/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01502-z

Other articles of this Issue 3/2024

Current Oncology Reports 3/2024 Go to the issue

REVIEW

Current Trends and Challenges of Microbiome Research in Bladder Cancer

REVIEW

Establishing an Integrative Oncology Service: Essential Aspects of Program Development

Review

The Dairy and Cancer Controversy: Milking the Evidence

Review

Geographical Disparities in Lung Cancer in Canada: A Review

REVIEW

Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer

REVIEW

Oral Health in Patients with History of Head and Neck Cancer: Complexity and Benefits of a Targeted Oral Healthcare Pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits